Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 13/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24078864 | 0.83 | NT5E (0.51) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL21450324 | 0.81 | NT5E (0.54) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL22843677 | 0.78 | NT5E (0.54) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL19370359 | 0.77 | NT5E (0.45) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL22843697 | 0.76 | NT5E (0.52) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL24078869 | 0.75 | NT5E (0.48) | NT5EADORA2A | |
| SCHEMBL21450286 | 0.74 | NT5E (0.50) | NT5E | |
| SCHEMBL24078892 | 0.73 | NT5E (0.57) | NT5E | |
| SCHEMBL22215019 | 0.73 | NT5E (0.47) | NT5EADORA3ADORA1ADORA2A | |
| SCHEMBL22843455 | 0.73 | NT5E (0.50) | NT5EADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | NT5E 10/4885ADORA3 19/4885ADORA1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.